Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model (original) (raw)

Nature Medicine volume 10, pages 1257–1260 (2004)Cite this article

Abstract

Bioluminescence imaging has previously been used to monitor the formation of grafted tumors in vivo and measure cell number during tumor progression and response to therapy. The development and optimization of successful cancer therapy strategies may well require detailed and specific assessment of biological processes in response to mechanistic intervention. Here, we use bioluminescence imaging to monitor the cell cycle in a genetically engineered, histologically accurate model of glioma in vivo. In these platelet-derived growth factor (PDGF)-driven oligodendrogliomas, G1 cell-cycle arrest is generated by blockade of either the PDGF receptor or mTOR using small-molecule inhibitors.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

References

  1. Sherr, C.J. & McCormick, F. The RB and p53 pathways in cancer. Cancer Cell 2, 103–112 (2002).
    Article CAS Google Scholar
  2. Johnson, D.G., Ohtani, K. & Nevins, J.R. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev. 8, 1514–1525 (1994).
    Article CAS Google Scholar
  3. Parr, M.J. et al. Tumor-selective transgene expression in vivo mediated by an E2F- responsive adenoviral vector. Nat. Med. 3, 1145–1149 (1997).
    Article CAS Google Scholar
  4. Contag, C.H. et al. Visualizing gene expression in living mammals using a bioluminescent reporter. Photochem. Photobiol. 66, 523–531 (1997).
    Article CAS Google Scholar
  5. Gelovani Tjuvajev, J. & Blasberg, R.G. In vivo imaging of molecular-genetic targets for cancer therapy. Cancer Cell 3, 327–332 (2003).
    Article Google Scholar
  6. Massoud, T.F. & Gambhir, S.S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 17, 545–580 (2003).
    Article CAS Google Scholar
  7. Choy, G. et al. Comparison of noninvasive fluorescent and bioluminescent small animal optical imaging. Biotechniques 35, 1022–1030 (2003).
  8. Contag, P.R., Olomu, I.N., Stevenson, D.K. & Contag, C.H. Bioluminescent indicators in living mammals. Nat. Med. 4, 245–247 (1998).
    Article CAS Google Scholar
  9. Holland, E.C. Gliomagenesis: genetic alterations and mouse models. Nat. Rev. Genet. 2, 120–129 (2001).
    Article CAS Google Scholar
  10. Dai, C. et al. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev. 15, 1913–1925 (2001).
    Article CAS Google Scholar
  11. Shih, A. et al. Dose dependent effects of PDGF-B on glial tumorigenesis. Cancer Res. (in press).
  12. Podsypanina, K. et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten +/− mice. Proc. Natl. Acad. Sci. USA 98, 10320–10325 (2001).
    Article CAS Google Scholar
  13. Burgos, J.S. et al. Time course of bioluminescent signal in orthotopic and heterotopic brain tumors in nude mice. Biotechniques 34, 1184–1188 (2003).
    Article CAS Google Scholar
  14. Rehemtulla, A. et al. Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia 2, 491–495 (2000).
    Article CAS Google Scholar
  15. Rehemtulla, A. et al. Molecular imaging of gene expression and efficacy following adenoviral-mediated brain tumor gene therapy. Mol. Imaging 1, 43–55 (2002).
    Article CAS Google Scholar
  16. Shah, K., Tang, Y., Breakefield, X. & Weissleder, R. Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. Oncogene 22, 6865–6872 (2003).
    Article CAS Google Scholar
  17. Dai, C. et al. The characteristics of astrocytomas and oligodendrogliomas are caused by two distinct interchangable signaling formats. Neoplasia (in the press).
  18. Garami, A. et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell 11, 1457–1466 (2003).
    Article CAS Google Scholar
  19. Rajasekhar, V.K. et al. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol. Cell 12, 889–901 (2003).
    Article CAS Google Scholar

Download references

Acknowledgements

The authors would like to thank C. Glaster for preparation of this manuscript, C. Discafani (Wyeth Research) for the CCI-779 and J. Wood (Novartis Pharmaceuticals) for the PTK787/ZK222584. This work was supported by the Tow, Seroussi, Bressler and Kirby Foundations.

Author information

Author notes

  1. Lene Uhrbom and Edward Nerio: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Genetics and Pathology, Uppsala University, Rudbeck Laboratory, Uppsala, SE-75185, Sweden
    Lene Uhrbom
  2. Departments of Surgery (Neurosurgery), Memorial Sloan-Kettering Cancer Center, Neurology and Cancer Biology and Genetics, RRL 917B, 1275 York Avenue, New York, 10021, New York, USA
    Lene Uhrbom, Edward Nerio & Eric C Holland

Authors

  1. Lene Uhrbom
    You can also search for this author inPubMed Google Scholar
  2. Edward Nerio
    You can also search for this author inPubMed Google Scholar
  3. Eric C Holland
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toEric C Holland.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Rights and permissions

About this article

Cite this article

Uhrbom, L., Nerio, E. & Holland, E. Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model.Nat Med 10, 1257–1260 (2004). https://doi.org/10.1038/nm1120

Download citation

This article is cited by